Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F3	Jul 27, 2015	X	53,857	$0.14	A	766,720	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F4,F3	Jul 27, 2015	S	3,390	$2.27	D	763,330	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F3	Jul 27, 2015	X	4,205	$0.14	A	767,535	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F4,F3	Jul 27, 2015	S	265	$2.27	D	767,270	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F3	Jul 27, 2015	X	4,205	$0.14	A	771,475	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F4,F3	Jul 27, 2015	S	265	$2.27	D	771,210	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F3	Jul 27, 2015	X	4,205	$0.14	A	775,415	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F4,F3	Jul 27, 2015	S	265	$2.27	D	775,150	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F3	Jul 27, 2015	X	4,205	$0.14	A	779,355	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F4,F3	Jul 27, 2015	S	265	$2.27	D	779,090	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F3	Jul 27, 2015	X	8,410	$0.14	A	787,500	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1,F4,F3	Jul 27, 2015	S	530	$2.27	D	786,970	I	Held by Applied Genomic Technology Capital Fund, L.P.
Common Stock^F1	holding	—	—		—	43,930	D
Common Stock^F1,F3	holding	—	—		—	53,754	I	Held by AGTC Advisors Fund, L.P.
Common Stock^F1,F10	holding	—	—		—	2,508	I	Held by Atlast LP
Common Stock^F1,F11	holding	—	—		—	441,072	I	Held by Flagship Ventures Fund 2007, L.P.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Warrant to Purchase Common Stock (right to buy)^F1,F3,F12	$0.14	Jul 27, 2015	X	53,857	D	—	Jul 28, 2015	Common Stock	53,857	I
Warrant to Purchase Common Stock (right to buy)^F1,F3,F12	$0.14	Jul 27, 2015	X	4,205	D	—	Sep 8, 2015	Common Stock	4,205	I
Warrant to Purchase Common Stock (right to buy)^F1,F3,F12	$0.14	Jul 27, 2015	X	4,205	D	—	Sep 28, 2015	Common Stock	4,205	I
Warrant to Purchase Common Stock (right to buy)^F1,F3,F12	$0.14	Jul 27, 2015	X	4,205	D	—	Nov 14, 2015	Common Stock	4,205	I
Warrant to Purchase Common Stock (right to buy)^F1,F3,F12	$0.14	Jul 27, 2015	X	4,205	D	—	Dec 15, 2015	Common Stock	4,205	I
Warrant to Purchase Common Stock (right to buy)^F1,F3,F12	$0.14	Jul 27, 2015	X	8,410	D	—	Mar 10, 2016	Common Stock	8,410	I

Explanation of responses

F1Share and price per share amounts have been adjusted to reflect a 1-for-4 reverse split of the Issuer's common stock on July 8, 2015.
F10Noubar B. Afeyan, Ph.D. is the general partner of Atlast LP and may be deemed to beneficially own the securities held by Atlast LP. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F11Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Dr. Afeyan and Mr. Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F12This warrant is immediately exercisable.
F2On July 27, 2015, Applied Genomic Technology Capital Fund, L.P. ("AGTCF") exercised warrants to purchase 53,857 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 3,390 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 50,467 shares.
F3NewcoGen Group, Inc. ("NG") is the general partner of AGTC Partners, L.P., which is the general partner of AGTCF and AGTC Advisors Fund, L.P. ("AGTCA", and together with AGTCF, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar B. Afeyan, Ph.D. is the director of Flagship and may be deemed to beneficially own the securities held by the AGTC Funds. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F4The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date.
F5On July 27, 2015, AGTCF exercised warrants to purchase 4,205 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 265 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 3,940 shares.
F6On July 27, 2015, AGTCF exercised warrants to purchase 4,205 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 265 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 3,940 shares.
F7On July 27, 2015, AGTCF exercised warrants to purchase 4,205 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 265 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 3,940 shares.
F8On July 27, 2015, AGTCF exercised warrants to purchase 4,205 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 265 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 3,940 shares.
F9On July 27, 2015, AGTCF exercised warrants to purchase 8,410 shares of Common Stock for $0.14 per share. AGTCF exercised the warrants on a cashless basis, resulting in the Issuer's withholding of 530 of the warrant shares to pay the exercise price and issuing to AGTCF the remaining 7,880 shares.